Brown Capital
Brown Capital Small Company Fund
Small-cap
Jun 2025 → Sep 2025
Our archive holds 2 letters from this strategy, behind 6 investment theses and positions in 6 companies. Every quote below is copied verbatim from the letter it came from.
2 letters in a year — follow all of Brown Capital for every strategy.
Its investment theses
- AxogenSep 2025Axogen offers the only approved human nerve graft with strong clinical evidence, high growth, and upcoming BLA exclusivity driving profitability.
- Corcept TherapeuticsSep 2025Corcept Therapeutics delivers high-margin cortisol-modulating therapies with robust revenue and income growth, strong cash flow, and a large R&D pipeline.
- GlaukosSep 2025Glaukos offers innovative glaucoma devices with strong revenue growth, FDA-approved implants, and a promising product pipeline.
- IntappSep 2025Intapp provides specialized industry software with high retention, competitive moat, AI integration, and a clear path to profitability.
- Mama’s CreationsSep 2025Mama’s Creations offers fresh deli and prepared foods with strong organic growth, low market penetration, and experienced management driving expansion.
- VericelSep 2025Vericel develops high-growth cell therapies for sports medicine and burns, with strong MACI adoption, seasonal demand, and product expansion.